New Paper Published in "Stem Cells" Reporting In-Vivo Migration Ability of BrainStorm Cell Therapeutics Inc.'s NTF Cells

NEW YORK & PETACH TIKVAH, Israel--(BUSINESS WIRE)--BrainStorm Cell Therapeutics Inc. (OTCBB:BCLI), a leading developer of adult stem cell technologies and therapeutics, is pleased to announce that the company’s new therapeutic approach for treating neurodegenerative disease was highlighted in a recent scientific paper that was published in “Stem Cells” highlighting the company’s patent technology for treating neurodegenerative diseases. “Stem Cells” is the most well known journal recording findings in the stem cell field. The paper was authored by Tel Aviv University scientists.

Back to news